Appeals court sides with Pfizer, Merck KGaA in $5bn suit
29-09-2020
Fed Circuit affirms generic maker’s win over Eagle
11-05-2020
Biogen takes Creative Biolabs to court over antibody
19-03-2020
felixlipov / Shutterstock.com
The US Court of Appeals for the Federal Circuit has affirmed a lower court’s decision which found that Banner Life Sciences wasn’t infringing a Biogen patent with its bioequivalent version of a multiple sclerosis drug.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Federal Circuit, Biogen, Banner Life Sciences, generics, multiple sclerosis, Tecfidera, Hatch-Waxman Act
